Novel immunotherapies for T cell lymphoma and leukemia Journal Article
| Authors: | Ghione, P.; Moskowitz, A. J.; De Paola, N. E. K.; Horwitz, S. M.; Ruella, M. |
| Article Title: | Novel immunotherapies for T cell lymphoma and leukemia |
| Abstract: | Purpose of Review: Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia. Recent Findings: For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. Summary: In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches. © 2018, Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | leukemia; allogeneic stem cell transplantation; mortality; review; phenotype; apoptosis; interleukin 10; interleukin 13; interleukin 4; interleukin 5; b cell lymphoma; t cell lymphoma; acute graft versus host disease; hematologic malignancy; immunotherapy; immunosuppressive treatment; autoimmune disease; leukocytosis; disease exacerbation; alemtuzumab; hepatosplenomegaly; programmed death 1 ligand 1; clinical outcome; systemic disease; t-all; anaplastic large cell lymphoma; brentuximab vedotin; nivolumab; human; pembrolizumab; immune checkpoint inhibitors; daratumumab; isatuximab; cart cell therapy; mogamulizumab |
| Journal Title: | Current Hematologic Malignancy Reports |
| Volume: | 13 |
| Issue: | 6 |
| ISSN: | 1558-8211 |
| Publisher: | Springer |
| Date Published: | 2018-12-01 |
| Start Page: | 494 |
| End Page: | 506 |
| Language: | English |
| DOI: | 10.1007/s11899-018-0480-8 |
| PROVIDER: | scopus |
| PMCID: | PMC6295363 |
| PUBMED: | 30317410 |
| DOI/URL: | |
| Notes: | Curr. Hematol. Malig. Rep. -- Cited By :1 -- Export Date: 2 January 2019 -- Review -- Source: Scopus C2 - 30317410 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work